公开(公告)号：US20230089392A1

公开(公告)日：2023-03-23

申请号：US17933418

申请日：2022-09-19

Applicant: Immatics US, Inc.

Inventor： Justin GUNESCH ,  Pooja MEHTA ,  Mamta KALRA

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74

Abstract: A method for producing an engineered T cell population includes obtaining a cell population containing a monocyte and a T cell, resting the obtained cell population on a surface, adhering the monocyte to the surface, retaining a non-adherent cell population, activating the non-adherent cell population, introducing a nucleic acid into the activated non-adherent cell population to obtain a transformed T cell, and expanding the transformed T cell to obtain the engineered T cell population.

公开(公告)号：US20230355678A1

公开(公告)日：2023-11-09

申请号：US18312144

申请日：2023-05-04

Applicant: IMMATICS US, INC.

Inventor： Pooja MEHTA ,  Rene TAVERA ,  Christopher LANIER ,  Mamta KALRA

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/999

Abstract: Methods of manufacturing T cells to improve their efficacy, persistence, memory function, and/or antigen stimulated survival are provided. Methods of manufacturing T cells to improve production of Central Memory T (Tcm) cells are provided. Methods may include culturing or treating T cells with one or more histone deacetylase inhibitor (HDACi) and interleukin-21 (IL-21), with one or more kinase inhibitor, such a tyrosine kinase inhibitor, and/or with one or more AKT inhibitor (AKTi).